Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 16 2024
0mins
Source: Benzinga
Edgewise Therapeutics Surge: Shares of Edgewise Therapeutics, Inc. rose 26.5% in pre-market trading after positive Phase 2 trial results for Sevasemten in Becker muscular dystrophy patients.
Market Movements: Several stocks saw significant pre-market gains, including Sidus Space (59.4%) and PureTech Health (22.8%), while Akoustis Technologies faced a sharp decline of 39.8% following a Chapter 11 filing.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
